Heart failure: old drugs with new tricks / Statin for everyone every time -is it right? 163 predicted the primary endpoint of hospitalisation for worsening HF or cardiovascular death (HR 1.38; 95% CI 1.15-1.64; p<0.001) and of all-cause mortality (HR 1.42; 95% CI 1.16-1.72; p<0.001). Ivabradine use was associated with a reduction of the primary composite endpoint both in patients with (HR, 0.82, 95% CI, 0.68 to 0.97), and without renal dysfunction (HR, 0.81, 95% CI, 0.71 to 0.91) (Pvalue

more »

... tion, 0.89). No differences were found in changes in renal function over time between ivabradine and placebo treated patients. Conclusion: In chronic stable systolic heart failure patients, heart rate was directly and independently associated with risk of WRF, but reduction in heart rate by ivabradine had a neutral effect on renal function during 2 years of follow-up. The effects of ivabradine were maintained both in patients with and without renal dysfunction.